Internship

Vertex Summer 2025 Intern

Clinical Data Management & Metrics

Posted on 2/27/2025

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$20 - $50/hr

No H1B Sponsorship

Boston, MA, USA

Category
Data Management
Data Analysis
Data & Analytics
Required Skills
Data Analysis
Requirements
  • Enrolled in an undergraduate or graduate program
  • Majors in Biotechnology, Data Analytics, Engineering or Life Sciences related field, or a related field of study
  • Permanent legal authorization to work in the United States
  • Candidate must be enrolled in an advanced degree program if graduating before May 2025
  • Candidate must be available to work full-time, 40 hours per week from May - August 2025
Responsibilities
  • Responsible for the clinical data strategy for all studies, programs, phases and therapeutic areas
  • Focus on learning the nuances of data analysis in a clinical trial setting
  • Help to revise the structure of the team Sharepoint site, consolidating information and making it more accessible
  • Updating country intelligence repository, QCing documents for IRB/EC submissions and filing said documents in the Trial Master File
  • Partner with a clinical program lead to refine processes across functions
  • Support ongoing department standardization and document development initiatives
  • Support the RBSM applications validation activities and continuous improvement of the risk-based study management process
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • EU approval for expanded cystic fibrosis treatment label boosts Vertex's market presence.
  • Partnership with Orna Therapeutics advances Vertex's gene-editing capabilities for genetic disorders.
  • Increased investment in rare disease research aligns with Vertex's focus on severe conditions.

What critics are saying

  • Rising competition in cystic fibrosis market may impact Vertex's market share.
  • High cost of gene-editing technologies could limit accessibility of Vertex's treatments.
  • Reliance on partnerships poses risks if partners face financial or operational difficulties.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on severe diseases, offering transformative treatments like ivacaftor for cystic fibrosis.
  • Strategic partnerships, such as with Arbor Biotechnologies, enhance Vertex's R&D capabilities.
  • Vertex's global operations and innovative therapies set it apart in the biotechnology sector.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

Biz Owner Daily
Apr 7th, 2025
EU Approves Expanded Label for Vertex Pharmaceuticals' Cystic Fibrosis Treatment

Vertex Pharmaceuticals has received approval from the European Union to broaden the label for its cystic fibrosis treatment.

Slater Sentinel
Mar 23rd, 2025
Stevens Capital Management LP Makes New $829,000 Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Stevens Capital Management LP makes new $829,000 investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Investing.com
Mar 20th, 2025
BMO maintains Vertex stock Market Perform rating and $41 target

The reaffirmation of the rating and target came after Vertex held its first analyst day since its initial public offering in 2020.

Stat News
Mar 18th, 2025
Genetics expert is first NIH director to leave under Trump

He will be replaced on an interim basis by Director Ian Smith, a former Vertex Pharmaceuticals executive.

GlobeNewswire
Mar 18th, 2025
Arbor Biotechnologies Announces $73.9 Million Series C Financing to Advance Novel Gene Editing Therapeutics

Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investors Financing extends Arbor’s cash runway into...

INACTIVE